| Tom Spalding, PA | |
|
205 Frasier St, Triangle Urology Associates, P.a., Durham, NC 27704-2125 | |
| (919) 477-7003 | |
| (919) 471-2827 |
| Full Name | Tom Spalding |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Location | 205 Frasier St, Durham, North Carolina |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083763007 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 100697 (North Carolina) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Tom Spalding, PA 205 Frasier St, Triangle Urology Associates, P.a., Durham, NC 27704-2125 Ph: (919) 477-7003 | Tom Spalding, PA 205 Frasier St, Triangle Urology Associates, P.a., Durham, NC 27704-2125 Ph: (919) 477-7003 |
News Archive
Five University of California, San Diego scientists and professors are among the first class of the Fellows of the American Association for Cancer Research Academy, created to recognize researchers whose scientific contributions have propelled significant innovation and progress against cancer.
The Center for Global Health Policy's "Science Speaks" blog rounds up results presented at a late breaker session at last week's 2nd International Treatment as Prevention Workshop in Vancouver. The blog notes the session "offered some interesting insights relevant to HIV treatment scale up."
Researchers revealed this Sunday a new heart valve that can be implanted without surgery. The device may hold promise for tens of thousands of elderly patients who might not survive a standard valve-replacement operation.
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced the acquisition of patents for DJ5, a novel non-TZD PPARgamma agonist with potential to retard progressive renal failure in patients with autosomal dominant polycystic kidney disease ("ADPKD').
Lannett Company, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Ondansetron Injection USP, 2 mg/mL, Multi-Dose Vials. Ondansetron Injection USP, 2 mg/mL is the generic equivalent of GlaxoSmithKline's Zofran® Injection, 2 mg/mL. For the 12 months ending December 2009 U.S. sales of Ondansetron Injection USP, 2 mg/mL were approximately $58 million at Average Wholesale Price (AWP). A launch date for the product has not yet been set.
› Verified 1 days ago
Dr. Karen Christine Baker, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 5704 Fayetteville Rd, Durham, NC 27713 Phone: 919-572-4673 Fax: 919-668-0321 | |
Dr. Thomas James Polascik, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: Duke Cancer Center 5-1 Urology, Duke Cancer Center, Duke University Medical Center, Durham, NC 27710 Phone: 919-684-4946 Fax: 919-684-5220 | |
Brant A Inman, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1000 Trent Dr, Durham, NC 27710 Phone: 919-684-8111 | |
Dr. Andrew Charles Peterson, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 40 Duke Medicine Cir, Durham, NC 27710 Phone: 919-684-2516 | |
Judd Moul, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 2100 Erwin Rd, Durham, NC 27710 Phone: 919-620-4467 | |
Daniel George, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: Duke University Medical Ctr, Durham, NC 27710 Phone: 919-620-4467 |